1
Groenland, Stefanie L., van Eerden, Ruben A. G., Verheijen, Remy B., Koolen, Stijn L. W., Moes, Dirk Jan A. R., Desar, Ingrid M. E., Reyners, Anna K. L., Gelderblom, Hans J., van Erp, Nielka P., Mathijssen, Ron H. J., Huitema, Alwin D. R., Steeghs, Neeltje
Veröffentlicht in: Dutch Pharmacology Oncology Grp , Groenland , S L , van Eerden , R A G , Verheijen , R B , Koolen , S L W , Moes , D J A R , Desar , I M E , Reyners , A K L , Gelderblom , H J , van Erp , N P , Mathijssen , R H J , Huitema , A D R & Steeghs , N 2019 , ' Therapeutic Drug Monitoring of Oral Anticancer Drugs : The Dutch Pharmacology Oncology Group-Therapeutic Drug Monitoring Protocol for a Prospective Study ' , Therapeutic Drug Monitoring , vol. 41 , no. 5 , pp. 561-567 . https://doi.org/10.1097/FTD.0000000000000654;
2019
Veröffentlicht in: Dutch Pharmacology Oncology Grp , Groenland , S L , van Eerden , R A G , Verheijen , R B , Koolen , S L W , Moes , D J A R , Desar , I M E , Reyners , A K L , Gelderblom , H J , van Erp , N P , Mathijssen , R H J , Huitema , A D R & Steeghs , N 2019 , ' Therapeutic Drug Monitoring of Oral Anticancer Drugs : The Dutch Pharmacology Oncology Group-Therapeutic Drug Monitoring Protocol for a Prospective Study ' , Therapeutic Drug Monitoring , vol. 41 , no. 5 , pp. 561-567 . https://doi.org/10.1097/FTD.0000000000000654;
2019